argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
argenx SE ADR ARGX
News
-
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
argenx to Present at Upcoming Investor Conferences
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Argenx Down Nearly 26%, on Pace for Record Percent Decrease — Data Talk
Argenx stock dives by a third after late-stage trial didn't meet goals
Argenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 — Data Talk
Argenx Shares Down After Vyvgart Study Misses Primary Endpoint
Argenx Launches $750 Million Global Offering
Argenx Up Over 30%, on Track for Record High Close — Data Talk
Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results
Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo
Argenx Says FDA Approves Vyvgart Hytrulo Injection to Treat Neuromuscular Disease gMG